BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7162464)

  • 1. Enzymology of cytosine arabinoside.
    Cheng YC; Capizzi RL
    Med Pediatr Oncol; 1982; 10 Suppl 1():27-31. PubMed ID: 7162464
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
    Chabot GG; Bouchard J; Momparler RL
    Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduction of ara-C cytotoxicity in HL 60 cells by addition of deoxycytidine, cytidine or increased level of cytidine deaminase.
    Mejer J; Mortensen BT
    Adv Exp Med Biol; 1989; 253B():335-9. PubMed ID: 2558539
    [No Abstract]   [Full Text] [Related]  

  • 4. Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia.
    Colly LP; Peters WG; Richel D; Arentsen-Honders MW; Starrenburg CW; Willemze R
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):257-61. PubMed ID: 3035720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deamination rates of 1-beta-D-arabinofuranosylcytosine, deoxycytidine and 5-methyl-2'-deoxycytidine in seven hematopoietic cell lines.
    Jekunen A
    Med Biol; 1987; 65(4):203-8. PubMed ID: 3437781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics and substrate specificity of human and canine cytidine deaminase.
    Fanucchi MP; Watanabe KA; Fox JJ; Chou TC
    Biochem Pharmacol; 1986 Apr; 35(7):1199-201. PubMed ID: 3964296
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia.
    Hagenbeek A; Martens AC; Colly LP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):202-6. PubMed ID: 3473677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia.
    Abraham A; Devasia AJ; Varatharajan S; Karathedath S; Balasubramanian P; Mathews V
    Ann Hematol; 2015 May; 94(5):883-5. PubMed ID: 25391240
    [No Abstract]   [Full Text] [Related]  

  • 9. Profiles of pyrimidine biosynthesis, salvage and degradation in disks of potato (Solanum tuberosum L.) tubers.
    Katahira R; Ashihara H
    Planta; 2002 Sep; 215(5):821-8. PubMed ID: 12244448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alkylated cytosine nucleosides: substrate and inhibitor properties in enzymatic deamination.
    Krajewska E; Shugar D
    Acta Biochim Pol; 1975; 22(2):185-94. PubMed ID: 1098340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic studies on possible improvement of cytosine arabinoside treatment.
    Mejer J
    Scand J Clin Lab Invest; 1981 Feb; 41(1):29-34. PubMed ID: 6942484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.
    Wan CW; Mak TW
    Cancer Res; 1978 Sep; 38(9):2768-72. PubMed ID: 679182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of cytosine arabinoside in Tetrahymena pyriformis.
    Benhura MA
    Comp Biochem Physiol B; 1985; 80(4):821-5. PubMed ID: 3922672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells.
    Coleman CN; Johns DG; Chabner BA
    Ann N Y Acad Sci; 1975 Aug; 255():247-51. PubMed ID: 171992
    [No Abstract]   [Full Text] [Related]  

  • 15. Pyrimidine pathways enzymes in human tumors of brain and associated tissues: potentialities for the therapeutic use of N-(phosphonacetyl-L-aspartate and 1-beta-D-arabinofuranosylcytosine.
    Madani S; Baillon J; Fries J; Belhadj O; Bettaieb A; Ben Hamida M; Hervé G
    Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1485-90. PubMed ID: 2824206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
    Onetto N; Momparler RL; Momparler LF; Gyger M
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):231-7. PubMed ID: 2438776
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
    Ohta T; Hori H; Ogawa M; Miyahara M; Kawasaki H; Taniguchi N; Komada Y
    Oncol Rep; 2004 Nov; 12(5):1115-20. PubMed ID: 15492802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside.
    Mancini WR
    Cancer Chemother Pharmacol; 1992; 30(2):139-44. PubMed ID: 1318170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of metabolism of cytosine arabinoside in L cells by antibody and complement.
    Shearer WT; Green CG; Mettes HJ
    Immunopharmacology; 1983 Oct; 6(3):203-14. PubMed ID: 6629738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
    Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
    Adv Exp Med Biol; 1994; 370():139-43. PubMed ID: 7660877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.